Clinical Trial Update: Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation [Phase 2]

View source ↗

Summary

Phase 2 study update on optimizing NULOJIX usage to minimize calcineurin inhibitor exposure in simultaneous pancreas and kidney transplantation; study terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Simultaneous Kidney and Pancreas Transplantation

Drugs mentioned

• Nulojix (belatacept)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Simultaneous Kidney and Pancreas Transplantation | Phase 2 | Status: TERMINATED | Results posted: 2017-12-07